<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.46624/ajptr.2018.v8.i5.023</article-id>
      <article-id pub-id-type="publisher-id">AJPTR85023</article-id>
      <title-group>
        <article-title>Design and In Vivo Evaluation of Quinapril Fast Dissolving Oral Films</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>P. Vamsee</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kumar</surname>
            <given-names>Y. Shravan</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2018-10-01">
        <month>10</month>
        <day>01</day>
        <year>2018</year>
      </pub-date>
      <volume>8</volume>
      <issue>5</issue>
      <abstract>
        <p>In current investigation an attempt has been made to formulate and evaluate Quinapril mouth dissolving films using HPMC 50cps, E5, E15 and in combination of Pullulan by Solvent evaporation method. Sodium starch glycolate acts as a super disintegrating agent and it is shown that as the concentration of the super disintegrates increases the disintegration time decreases. The films were evaluated for weight variation, surface pH, folding endurance, drug content, dissolving time, disintegration time, and in-vitro dissolution studies. Based on the evaluation parameters F17 was to be optimized formulation. The optimized film (F17) showed the more drug release i.e 99.40±5.30% within 7 min, lowest in vitro disintegration time 10 sec. FTIR studies proved no drug polymer interaction takes place. From in vivo bioavailability studies, Cmax of the optimized formulation F17 was 72.43±0.3ng /ml, was significantly higher as compared to pure drug suspension, i.e., 42.32±0.1ng/ml. Tmax of optimized formulation was decreased significantly when compared with pure drug (1.00±0.05hr, 2.00±0.1hr), AUC0-∞ and AUC0-t for optimized films was significantly higher (p</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Quinapril</kwd>
        <kwd>Mouth dissolving films</kwd>
        <kwd>Hypertension</kwd>
        <kwd>Bioavailability studies</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
